甲苯咪唑(Mebendazole) - 药物靶点：TNIK_在研适应症：鞭虫病，脑干胶质瘤，弥漫内生性脑桥神经胶质瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(5-benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester、MBDZ、Mebendazole (JAN/USP/INN)

+ [8]

靶点

TNIK

作用机制

TNIK抑制剂(肿瘤坏死因子受体相关因子-2和NCK相互作用蛋白激酶抑制剂)

治疗领域

感染肿瘤神经系统疾病+ [2]

在研适应症

鞭虫病脑干胶质瘤弥漫内生性脑桥神经胶质瘤+ [5]

非在研适应症

贫血蛔虫病蛲虫病+ [1]

原研机构

Johnson & Johnson

在研机构

Janssen Pharmaceuticals, Inc.Janssen Pharmaceutical KK

非在研机构

Janssen Research & Development LLC

Johns Hopkins Bloomberg School of Public HealthJohnson & Johnson Pharmaceutical Research & Development LLC

最高研发阶段批准上市

首次获批日期

美国 (1974-06-28),

蛔虫病蛲虫病钩虫感染+ [1]

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构

分子式C16H13N3O3

InChIKeyOPXLLQIJSORQAM-UHFFFAOYSA-N

CAS号31431-39-7

关联

45

项与甲苯咪唑相关的临床试验

NCT06335160 / Not yet recruitingN/AIIT

Clinical Study to Evaluate the Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine

To evaluate the possible efficacy and safety of mebendazole in patients with ulcerative colitis treated with mesalamine

开始日期2024-04-01

申办/合作机构

Tanta University

CTRI/2023/01/049248 / Recruiting临床3期IIT

A phase 3 study of CCNU versusCCNU plus mebendazole in glioma. - None

开始日期2023-02-01

申办/合作机构-

IRCT20220115053713N2 / Recruiting临床3期IIT

To investigate the therapeutic potency of Mebendazole in combination with standard treatment, mesalamine, in Ulcerative colitis patients

开始日期2022-04-21

申办/合作机构

Mashhad University of Medical Sciences

100 项与甲苯咪唑相关的临床结果

登录后查看更多信息

100 项与甲苯咪唑相关的转化医学

登录后查看更多信息

100 项与甲苯咪唑相关的专利（医药）

登录后查看更多信息

2,168

项与甲苯咪唑相关的文献（医药）

2024-10-01·EXPERIMENTAL PARASITOLOGY

PLGA-PEG-COOH nanoparticles are efficient systems for delivery of mefloquine to Echinococcus multilocularis metacestodes

Article

作者: Amela-Cortes, Marian ; Lundstroem-Stadelmann, Britta ; Autier, Brice ; Aninat, Caroline ; Plaisse, Charleen ; Preza, Matias ; Chollet-Krugler, Marylène ; Verger, Alexis ; Samson, Michel ; Dion, Sarah ; Manuel, Christelle ; Brandhonneur, Nolwenn

Alveolar echinococcosis (AE) is a severe disease caused by the infection with the larval stage of Echinococcus multilocularis, the metacestode. As there is no actual curative drug therapy, recommendations to manage AE patients are based on radical surgery and prophylactic administration of albendazole or mebendazole during 2 years to prevent relapses. There is an urgent need for new therapeutic strategies for the management of AE, as the drugs in use are only parasitostatic, and can induce toxicity. This study aimed at developing a drug delivery system for mefloquine, an antiparasitic compound which is highly active against E. multilocularis in vitro and in experimentally infected mice. We formulated mefloquine-loaded PLGA-PEG-COOH (poly-(lactic-co-glycolic acid)) nanoparticles that exhibit stable physical properties and mefloquine content. These nanoparticles crossed the outer acellular laminated layer of metacestodes in vitro and delivered their content to the inner germinal layer within less than 5 min. The in vitro anti-echinococcal activity of mefloquine was not altered during the formulation process. However, toxicity against hepatocytes was not reduced when compared to free mefloquine. Altogether, this study shows that mefloquine-loaded PLGA-PEG-COOH nanoparticles are promising candidates for drug delivery during AE treatment. However, strategies for direct parasite-specific targeting of these particles should be developed.

2024-09-11·Revista Espanola de Quimioterapia

Refractory Enterobius vermicularis infection in an elderly woman: Mebendazole or albendazole?

Letter

作者: Carranza-Rodríguez, C ; Tosco-Nuñez, T ; Pérez-Arellano, J L ; Suárez-Hormiga, J ; Jaén-Sánchez, N

2024-09-03·The American journal of tropical medicine and hygiene

A Mixed-Methods Evaluation of Mainstreaming Mass Drug Administration for Schistosomiasis and Soil-Transmitted Helminthiasis in Four Districts of Nigeria

Article

作者: Ugbadamu, Paul ; Griswold, Emily ; Poko, Happiness ; Amayat, Goodluck James ; Emukah, Emmanuel C. ; Danboyi, Jacob ; Rakers, Lindsay ; Ndudi, Okocha ; Eigege, Abel ; Coalson, Jenna ; Gallagher, Jayden Pace ; Miri, Emmanuel S. ; Anighoro, Vincent ; Unukopia, Regina Ese ; Mancha, Bulus ; Noland, Gregory S. ; Otabor, Esther ; Dikedi, Philomena ; Gwong, Christiana Davou ; Dagwa, Philemon

ABSTRACT.:

In Nigeria, mass drug administration (MDA) for schistosomiasis (SCH) and soil-transmitted helminthiasis (STH) has often been coordinated with other programs that receive greater external funding. As these programs reach stop MDA milestones, SCH and STH programs will likely need to transition implementation, or “mainstream,” to domestic support. A mixed-methods study was conducted in four districts before (2021) and after (2022) mainstreaming to evaluate its impact on MDA coverage. Household surveys were done in 30 villages per district pre- and post-mainstreaming. All selected communities were eligible for STH treatment; around a third were eligible for SCH treatment. Mass drug administration was primarily conducted in schools. A total of 5,441 school-aged children were included in pre-mainstreaming and 5,789 were included in post-mainstreaming. Mass drug administration coverage was heterogeneous, but overall, mebendazole coverage declined nonsignificantly from 81% pre-mainstreaming to 76% post-mainstreaming (P = 0.09); praziquantel coverage declined significantly from 73% to 55% (P = 0.008). Coverage was significantly lower among unenrolled children or those reporting poor school attendance in nearly every survey. For the qualitative component, 173 interviews and 74 focus groups were conducted with diverse stakeholders. Respondents were deeply pessimistic about the future of MDA after mainstreaming and strongly supported a gradual transition to full government ownership. Participants formulated recommendations for effective mainstreaming: clear budget allocation by governments, robust and targeted training, trust building, and comprehensive advocacy. Although participants lacked confidence that SCH and STH programs could be sustained after reductions in external support, initial results indicate that MDA coverage can remain high 1 year into mainstreaming.

7

项与甲苯咪唑相关的新闻（医药）

2024-02-14

·Science Daily

Controlling root growth direction could help save crops and mitigate climate change

Scientists have determined how the well-known plant hormone ethylene is crucial in controlling the angle at which roots grow. The findings can be used to engineer plants and crops that withstand the environmental stresses of climate change and drought, and perhaps to create plants that remove carbon dioxide from the atmosphere and store it deep underground to help mitigate climate change. Above ground, plants stretch toward the sun. Below ground, plants tunnel through the earth. As roots soak up water and nutrients from surrounding soil, they grow and stretch to develop distinct root system architectures. The root system architecture determines whether roots remain in the shallow soil layers or grow steeper and reach deeper soil layers. Root systems are central to plant survival and productivity, determining the plant's access to nutrients and water and, therefore, the plant's ability to withstand nutrient depletion and extreme weather like drought. Now, Salk scientists have determined how a well-known plant hormone is crucial in controlling the angle at which roots grow. The study, published in Cell Reports on February 13, 2024, is the first time the hormone, called ethylene, has been shown to be involved in regulating lateral root angles that shape root systems -- making the findings a revelation for plant scientists optimizing root systems. Researchers in Salk's Harnessing Plants Initiative now plan to target the ethylene signaling pathway in their efforts to engineer plants and crops that can withstand the environmental stresses of climate change and drought, as well as removecarbon dioxide from the atmosphere and store it deep underground to help mitigate climate change. "Deep roots lead to more durable carbon storage in the soil and can make plants more resistant to drought, so the ability to control how deep roots grow is really exciting for scientists looking to engineer better root systems," says senior author Wolfgang Busch, professor, executive director of the Harnessing Plants Initiative, and Hess Chair in Plant Science at Salk. "We're especially excited that the pathway we found is conserved across many types of plants, meaning our findings can be widely applied to optimize root architecture in all land plants, including food, feed, and fuel crops." Environmental factors -- like average rainfall or abundance of certain nutrients -- can influence the shape of a plant's root system. The angle at which roots grow produces different results in overall root architecture, with horizontal root angles creating a shallower root system and vertical root angles creating a deeper root system. But scientists did not understand clearly how these root angles were being determined on a molecular level. Plant hormones like auxin and cytokinin have been connected to the angle of root growth in the past, but the mechanisms of that connection have remained poorly understood. In searching for molecules and pathways that were involved in setting the angle of root growth, the team genetically screened Arabidopsis thaliana -- a small flowering weed in the mustard family -- for root system changes in response to thousands of molecules. "We noticed this molecule called mebendazole was causing the roots to grow more horizontally," says first author Wenrong He, a former postdoctoral researcher in Busch's lab. "When we looked for what target proteins or pathways mebendazole was interacting with to have this effect, we discovered it was ethylene signaling -- and ethylene playing such an essential role in root system architecture was really intriguing." The team observed that genes throughout the ethylene signaling pathway were activated in response to mebendazole, and, in turn, the pathway was carrying out the resulting changes in root growth. Biochemical investigation of this relationship revealed that mebendazole inhibits the activity of a protein kinase called CTR1. This enzyme negatively regulates ethylene signaling, in turn promoting a shallow root system. "Since ethylene signaling is a widely conserved process in land plants, targeting the ethylene pathway is a very promising technique for root system engineering," says Busch. "Hopefully, now we'll be able to use this tool to make crop species more resilient, and to create Salk Ideal Plants® that sequester more carbon underground to assist in the fight against climate change." The newfound implication of ethylene in root system architecture inspires new questions, including whether another molecule exists that -- unlike mebendazole -- makes root systems deeper, or if there are specific genes in the already well-cataloged ethylene signaling pathway that can be targeted most effectively to promote deeper roots in crops and Salk Ideal Plants. Other authors include Hai An Truong, Ling Zhang, Min Cao, and Kaizhen Zhong of Salk; Neal Arakawa of UC San Diego; Yao Xiao of the Scripps Research Institute; and Yingnan Hou of UC Riverside and Shanghai Jiao Tong University in China. The work was supported by Salk's Harnessing Plants Initiative, a Salk Women & Science Special Award, a Pioneer Fund Postdoctoral Scholar Award, the National Institutes of Health (NIH-NCI CCSG: P30 CA01495, NIH-NIA San Diego Nathan Shock Center P30 AG068635), Chapman Foundation, and Helmsley Charitable Trust.

2023-10-20

·Johnson & Johnson

Janssen Announces Promising Antiviral Activity Against Dengue in a Phase 2a Human Challenge Model

Chicago, Illinois (October 20, 2023) – The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today promising data from a Phase 2a human challenge study evaluating JNJ-1802, a first-in-class oral antiviral in development for the prevention of dengue. The data showed that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo, and is safe and well-tolerated. The data were announced at the American Society of Tropical Medicine & Hygiene Annual Meeting in Chicago, Illinois.JNJ-1802 is the first antiviral to show such activity in humans during a clinical trial. The compound has advanced to a community-based field study to establish efficacy against circulating dengue serotypes in a real-world setting. The study is being conducted in 30+ sites in 10 countries, including Philippines, Thailand, Peru, Brazil and Colombia.“Climate change threatens to put more people at risk of dengue, yet the world lacks the necessary tools to combat this significant health challenge,” said Ruxandra Draghia-Akli, M.D., Ph.D., Global Head, Global Public Health R&D at Janssen Research & Development, LLC. “For over a decade, we have been committed to following the science to bring forward new solutions for dengue and this new data is an encouraging step forward to addressing the expanding impact of climate change on human health.”The two-center, randomized, double-blind, placebo-controlled human challenge study evaluated the antiviral activity, safety and pharmacokinetics of different dosing regimens – low, medium or high – of JNJ-1802 against an attenuated dengue 3 serotype (DENV-3) in healthy adults. All participants received daily doses of JNJ-1802 or a placebo over 26 days, during which they were challenged with DENV-3 on day 5. All participants were monitored over 85 days. The study found dose-dependent antiviral effect on the detectability of DENV-3 RNA and time to first onset of detectable DENV-3 RNA compared to placebo and was safe and well-tolerated.“The promising results of JNJ-1802 to date offer the hope that science will be able to deliver against this threat as more and more communities are impacted worldwide,” said Marnix Van Loock, Ph.D., Lead for Emerging Pathogens, Global Public Health R&D at Janssen Pharmaceutica NV. “Dengue requires global action, and we are proud to collaborate alongside partners around the world in advancing the development of this compound to its next phase.”This study follows data published in Nature in March 2023, which showed that JNJ-1802 provides strong protection against dengue in non-human primates and mice, and a Phase 1 first-in-human clinical study showing that the antiviral was safe and well-tolerated.Janssen thanks its supporting partners including the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Division of Clinical Research (DCR and Office of Clinical Research Policy and Regulatory Operations (OCRPRO) for their collaboration in conducting this trial.A New Tool to Fight a Growing ThreatThe development of a dengue antiviral is critically important to global health. Over half the world’s population currently lives in areas where dengue is endemic. Dengue fever impacts at least 400 million annually, sickening an estimated 100 million and killing thousands, with more going undiagnosed or misdiagnosed.Changes in climate are exacerbating the crisis, lengthening the infection season and allowing the mosquito that carries the virus to spread beyond its native regions. In 2023, countries like Bolivia, Peru and Bangladesh have already reported some of their worst outbreaks on record, and countries like the U.S., Spain and France are seeing a rise of locally acquired cases for the first time.Research and development (R&D) against dengue has proven challenging due to four globally circulating serotypes and there are currently no therapeutics and only two licensed vaccines limitedly available. Investment in antivirals, which do not require cold chain and can induce immunity in just days, is sorely needed to diversify the prevention toolbox to slow down outbreaks and limit epidemic-levels of cases.Johnson & Johnson’s Commitment to DengueJohnson & Johnson has been investing in dengue R&D for over a decade. The Company is also collaborating closely with academic partners to bolster local R&D. In June 2022, Johnson & Johnson launched its Satellite Center for Global Health Discovery at Duke-NUS in Singapore, which is focused on accelerating early-stage discovery research to address the growing challenge of flaviviruses, including dengue.These efforts are part of Johnson & Johnson’s more than 15-year legacy working to address the burden of neglected tropical diseases (NTDs), a group of about 20 communicable diseases that together affect more than 1.7 billion people in 149 countries around the world. In 2022, the Company joined the global community to endorse the Kigali Declaration on Neglected Tropical Diseases, pledging to continue to donate up to 200 million doses annually of mebendazole through 2025 to tackle intestinal worms and advance novel R&D programs to discover new medications needed to beat leprosy and dengue.You can learn more about our efforts to beat NTDs, including dengue, by visiting JNJ.com/NTDs.  About the Janssen Pharmaceutical Companies of Johnson & JohnsonAt Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.Learn more at www.janssen.com. Follow us at @JanssenUS and @JanssenGlobal. Janssen Research & Development, LLC and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/. Cautions Concerning Forward-Looking Statements This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding dengue fever, flavivirus and neglected tropical diseases. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Pharmaceutica NV and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Pharmaceutica NV nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

临床2期疫苗临床结果临床1期

2023-09-15

·蒲公英Ouryao

再见，杨森制药！

转自：蒲公英Ouryao 综合：无忧9月14日，强生公司宣布品牌更新，将旗下医疗科技和制药两大业务整合至强生（Johnson&Johnson）名下。其中，公司制药部门杨森将更名为强生创新制药，医疗科技部门则保持不变。136年历史上最大的一次拆分9月14日，强生公司宣布品牌更新，将旗下医疗科技和制药两大业务整合至强生（Johnson&Johnson）名下。其中，公司制药部门杨森将更名为强生创新制药，医疗科技部门则保持不变。此次分拆是强生136年历史上最大的一次改组，预计将在明年完成。强生创新制药（Johnson&Johnson Innovative Medicine）专注于肿瘤、免疫、神经、心血管、肺动脉高压和视网膜等领域，以应对当今时代最复杂的疾病，并为未来开发前沿药物。今年1月24日，强生发布的2022财年最新数据显示，强生营收 949.4亿美元，其中制药业务营收525.6亿美元；拆分完成后，对于“新强生”，在今年初的JPM大会上，强生新任首席执行官Joaquin Duato表示，到2025年整体业务目标是达成800亿美元。为了实现这一目标，强生计划到2025年为现有13种重磅产品提交36份新适应症申请，这些产品将是到2025年业绩增长的主要动力。制药界奇才杨森1926年，保罗·杨森出生于比利时弗拉芒语区的小镇特恩哈特；1951年，保罗·杨森在根特大学完成临床培训，并成功获得医学博士学位。Perdolan：同年，保罗·杨森依靠求学期间获得的药理学知识，他以常见的德国止痛剂作为参照，结合乙酰氨基酚、阿司匹林和咖啡因研制出一种新产品Perdolan，后来这款产品成为了比利时最广泛使用的止痛剂之一。异丙胺：1954年，保罗·杨森在实验室成功制成了异丙胺——一种可抑制胃肠道平滑肌痉挛，并阻断胃液分泌的长效抗胆碱能药物。这一产品的生产许可随即被卖给了史克必成（2000年，史克必成与葛兰素威廉合并成为葛兰素史克），并为保罗·杨森带来了维持实验室运行的重要资金。在保罗·杨森的领导下，公司开发出一系列产品： 1956年，他主持开发了哌替啶的类似物，用于治疗腹泻的地芬诺酯（R1132），这个药物甚至进入了太空，在阿波罗计划中使用； 1966年，左旋咪唑（R12564），抗蠕虫药； 1967年，咪康唑（R14889），抗霉菌药； 1968年，甲苯咪唑（R17635），抗蠕虫药； 1969年，止泻药洛哌丁胺（R18553）（易蒙停）研制成功。它能高效抑制肠道运动，且无法穿越血脑屏障，后成为杨森最著名的药品之一； 1969年，抑霉唑（R23979），抗霉菌药物； 1974年，舒芬太尼（R30730），镇痛药； 1975年，丙环唑（R35432）（R49362），抗真菌药； 1976年，酮康唑（R41400），抗真菌药； 1984年，利培酮（R64766），精神安定药…… 在保罗·杨森博士的领导下，杨森制药分部壮大，一跃而成为世界知名的制药大公司，开发了100，000种以R开头编号的化合物，其中有80种已被作为人用、动物用和植物用药品开发；四个药物被列入世界卫生组织的基本药物目录！这绝对是一个世界纪录。他和他的团队开发的大多数药物为人类医学发展做出了贡献，被用来治疗真菌和寄生虫感染疾病，精神疾病，心血管疾病，过敏和胃肠道疾病。西安杨森，制药人的黄埔军校1976年，杨森博士在西安参观兵马俑时，发现泥土和空气中霉菌的腐蚀，正加速秦始皇兵马俑的颜色褪去后，向西安市捐赠一批抗真菌剂，来保护这些文物。自此，杨森与中国医药的命运齿轮开始转动... 1985年，美国强生子公司比利时杨森与中方四家制药公司（陕西省医药总公司、陕西省汉江药业股份有限公司、中国医药工业公司、中国医药对外贸易总公司）联合投资成立西安杨森。作为中国最大的合资制药企业、美国强生公司在华最大的子公司，西安杨森生产和销售涉及胃肠病学、神经精神学、变态反应学、疼痛管理学、抗感染、生物制剂和肿瘤等领域的高质量药品。除此多外西安杨森被认为与一般意义上的外资制药公司不同之处在于，它大规模系统地培育了中国第一代真正意义上的医药代表，将西方先进的学术推广等方式带入中国医药行业，大幅提高了国内临床医生对药物的认知水平。不仅如此，几乎所有在西安杨森供职过的人对其内部培训和职业成长计划都评价颇高。西安杨森的每名员工平均每年可以接受100小时有针对性的系统培训，其中10%的员工有机会接受海外培训。一个细节是，在上世纪80年代的西安杨森，每个人都被要求走上讲台进行3~15分钟不等的主题演讲，这种具有鲜明美国元素的训练方式，成就了此后活跃于中国医药领域最优秀的一批职业经理人。西安杨森被一致誉为业内的“黄埔军校”，曾在中国医药发展的历史上留下不可磨灭，浓墨重彩的一笔。参考：企业公告医学论坛网新康界

财报

100 项与甲苯咪唑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00368	甲苯咪唑	P02CA01	DB00643

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
蛔虫病	美国	Janssen Pharmaceuticals, Inc.	1974-06-28
蛲虫病	美国	Janssen Pharmaceuticals, Inc.	1974-06-28
钩虫感染	美国	Janssen Pharmaceuticals, Inc.	1974-06-28
鞭虫病	美国	Janssen Pharmaceuticals, Inc.	1974-06-28

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
蠕虫病	临床3期	埃塞俄比亚	Janssen Research & Development LLC	2014-12-01
蠕虫病	临床3期	卢旺达	Janssen Research & Development LLC	2014-12-01
寄生虫病	临床3期	坦桑尼亚	Johnson & Johnson Pharmaceutical Research & Development LLC	2010-02-01
贫血	临床3期	巴基斯坦	Johns Hopkins Bloomberg School of Public Health	2004-04-01
脑干胶质瘤	临床2期	美国	Janssen Pharmaceuticals, Inc.	2013-10-22
弥漫内生性脑桥神经胶质瘤	临床2期	美国	Janssen Pharmaceuticals, Inc.	2013-10-22
多形性胶质母细胞瘤	临床2期	美国	Janssen Pharmaceuticals, Inc.	2013-10-22
神经胶质肉瘤	临床2期	美国	Janssen Pharmaceuticals, Inc.	2013-10-22
低级神经胶质瘤	临床2期	美国	Janssen Pharmaceuticals, Inc.	2013-10-22
视神经胶质瘤	临床2期	美国	Janssen Pharmaceuticals, Inc.	2013-10-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


CTRI/2018/01/011542 (BELOB, ASCO2022) 人工标引	临床2期	复发性胶质母细胞瘤	-	lomustine+Mebendazole	簾鬱願鏇窪淵顧鹹鹹簾(簾觸範願觸鹹淵繭鹹夢) = 獵鹹鑰餘鹽獵廠廠網襯顧鏇蓋廠網壓構觸鑰觸 (糧夢糧遞鏇壓夢簾衊廠, 29.6 ~ 59.2) 更多	不佳	2022-06-02
				temozolomide+Mebendazole	簾鬱願鏇窪淵顧鹹鹹簾(簾觸範願觸鹹淵繭鹹夢) = 積鏇築鑰齋積願齋壓製顧鏇蓋廠網壓構觸鑰觸 (糧夢糧遞鏇壓夢簾衊廠, 22.3 ~ 51) 更多
NCT03925662 (Pubmed \| Life Sci) 人工标引	临床3期	转移性结直肠癌	40	Mebendazole + bevacizumab + FOLFOX4	選蓋齋衊糧艱鹽餘壓顧(醖艱願餘顧鹹窪蓋衊範): P-Value = 0.063 更多	积极	2022-04-03
				Bevacizumab + FOLFOX4 + placebo
NCT03995680 (CHEW_MEB_PEMBA, CTgov)	临床2期	钩虫感染	397	Mebendazole (Chewable Tablet of Mebendazole)	窪獵繭範鑰糧製鏇窪遞(淵壓齋網選鏇網觸廠齋) = 齋觸鑰醖憲積蓋願簾範築窪艱餘網觸壓鬱膚鹹 (鬱鏇製構鹹簾鹽齋鹽鹹, 壓壓積淵築觸繭簾遞齋 ~ 築淵顧蓋壓構鑰鏇鬱淵) 更多	-	2020-07-20
				Mebendazole (Swallowable Tablet of Mebendazole)	窪獵繭範鑰糧製鏇窪遞(淵壓齋網選鏇網觸廠齋) = 醖鹽積廠選簾淵製鑰鏇築窪艱餘網觸壓鬱膚鹹 (鬱鏇製構鹹簾鹽齋鹽鹹, 窪築遞觸蓋願壓顧夢選 ~ 願糧醖憲糧繭餘鑰鹹窪) 更多
NCT03245398 (CTgov)	临床4期	钩虫感染	186	one of the two regimens of mebendazole (Single Dose of Mebendazole)	廠簾製範鹽鹹齋糧築壓(蓋獵憲艱鹹簾鏇鹹積網) = 鏇衊鬱憲廠壓壓糧構齋顧獵淵獵選艱構憲膚鬱 (獵顧遞選鏇範願遞膚鏇, 糧獵糧壓製觸壓鏇鏇範 ~ 壓構廠構網積簾範鏇膚)	-	2019-06-17
				one of the two regimens of mebendazole (Multiple Dose of Mebendazole)	廠簾製範鹽鹹齋糧築壓(蓋獵憲艱鹹簾鏇鹹積網) = 壓艱糧餘糧獵願簾壓鹹顧獵淵獵選艱構憲膚鬱 (獵顧遞選鏇範願遞膚鏇, 糧簾憲製壓遞夢選網蓋 ~ 淵遞廠窪範願積鹽齋鏇)
NCT03245398 (Pubmed) 人工标引	临床4期	钩虫感染	185	Single dose mebendazole	鑰鹽夢餘願獵壓糧壓網(觸鬱壓艱範餘製築艱糧) = 蓋齋壓鹹鏇遞鏇憲膚醖簾衊壓鏇齋糧蓋鏇鹹觸 (遞廠糧願齋顧膚夢顧顧 ) 更多	积极	2018-07-01
				Multiple dose mebendazole	鑰鹽夢餘願獵壓糧壓網(觸鬱壓艱範餘製築艱糧) = 顧獵簾鹹夢衊鹽艱範蓋簾衊壓鏇齋糧蓋鏇鹹觸 (遞廠糧願齋顧膚夢顧顧 ) 更多
NCT02034162 (CTgov)	临床3期	蠕虫病	295	placebo (Double-blind Placebo)	觸憲繭鏇壓糧積獵鹹鑰(簾襯鹹夢齋製齋築膚夢) = 醖憲築積廠廠淵襯顧廠製廠鏇築遞鏇憲構鹹鏇 (廠膚構餘顧獵築鏇鹹繭, 艱遞觸鏇簾齋壓窪憲衊 ~ 蓋艱範願糧艱構齋廠襯) 更多	-	2016-11-04
				Mebendazole (Double-blind Mebendazole 500 mg)	觸憲繭鏇壓糧積獵鹹鑰(簾襯鹹夢齋製齋築膚夢) = 壓顧壓觸鹽廠鏇鑰鏇鑰製廠鏇築遞鏇憲構鹹鏇 (廠膚構餘顧獵築鏇鹹繭, 衊鹽鬱選壓積製壓衊餘 ~ 餘夢構遞衊遞夢糧構夢) 更多
NCT01379326 \| NCT01087099 (Pubmed \| PLoS Negl Trop Dis) 人工标引	临床4期	蠕虫病	250	Mebendazole 500 mg	艱積積構構鹽廠築醖鏇(簾膚醖窪蓋糧製鬱鹽遞) = 遞窪憲顧鹹醖繭蓋鏇範繭積窪壓膚鏇襯壓窪壓 (壓夢淵鹽廠艱廠淵餘製, 95.8 ~ 99.5) 更多	积极	2014-10-01
				Albendazole 400 mg	艱積積構構鹽廠築醖鏇(簾膚醖窪蓋糧製鬱鹽遞) = 廠願構廠糧齋糧壓製艱繭積窪壓膚鏇襯壓窪壓 (壓夢淵鹽廠艱廠淵餘製, 99.0 ~ 100) 更多
NCT01350271 (CTgov)	临床3期	蠕虫病	214	Placebo (Placebo)	夢製鹹選廠遞觸遞獵襯(簾鏇夢構蓋鑰製網廠糧) = 觸淵獵齋壓膚願鹹遞醖窪壓構積齋壓餘顧築簾 (壓遞鏇鬱築齋積鑰夢遞, 淵鏇齋選選膚餘構齋網 ~ 淵遞齋衊範夢積鬱鑰蓋) 更多	-	2013-04-22
				Mebendazole polymorph A (Mebendazole Polymorph A and C 500 mg)	夢製鹹選廠遞觸遞獵襯(簾鏇夢構蓋鑰製網廠糧) = 網鬱鏇鹹遞網築觸繭鑰窪壓構積齋壓餘顧築簾 (壓遞鏇鬱築齋積鑰夢遞, 網觸襯遞鹹襯齋遞艱鹹 ~ 淵糧鬱艱鹹餘衊選繭積) 更多
ERS2012 人工标引	N/A	持续性哮喘 total IgE \| Ascaris-specific IgE	24	Mebendazole	衊鑰衊鹽觸壓網積艱鬱(遞廠願廠鹹糧廠網廠鬱) = 簾簾衊鏇鏇醖膚範淵鑰壓觸網簾壓鏇遞鹹鹽淵 (觸鬱夢觸鬱範顧觸築積 ) 更多	积极	2012-09-01